Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Cytochrome c oxidase dysfunction enhances phagocytic function and osteoclast formation in macrophages.

Angireddy R, Kazmi HR, Srinivasan S, Sun L, Iqbal J, Fuchs SY, Guha M, Kijima T, Yuen T, Zaidi M, Avadhani NG.

FASEB J. 2019 May 7:fj201900010RR. doi: 10.1096/fj.201900010RR. [Epub ahead of print]

PMID:
31063702
2.

The PKR-Like Endoplasmic Reticulum Kinase Promotes the Dissemination of Myc-Induced Leukemic Cells.

Gui J, Katlinski KV, Koumenis C, Diehl JA, Fuchs SY.

Mol Cancer Res. 2019 Mar 22. doi: 10.1158/1541-7786.MCR-19-0002. [Epub ahead of print]

PMID:
30902831
3.

An Interferon-Driven Oxysterol-Based Defense against Tumor-Derived Extracellular Vesicles.

Ortiz A, Gui J, Zahedi F, Yu P, Cho C, Bhattacharya S, Carbone CJ, Yu Q, Katlinski KV, Katlinskaya YV, Handa S, Haas V, Volk SW, Brice AK, Wals K, Matheson NJ, Antrobus R, Ludwig S, Whiteside TL, Sander C, Tarhini AA, Kirkwood JM, Lehner PJ, Guo W, Rui H, Minn AJ, Koumenis C, Diehl JA, Fuchs SY.

Cancer Cell. 2019 Jan 14;35(1):33-45.e6. doi: 10.1016/j.ccell.2018.12.001.

PMID:
30645975
4.

Estrogen-dependent DLL1-mediated Notch signaling promotes luminal breast cancer.

Kumar S, Srivastav RK, Wilkes DW, Ross T, Kim S, Kowalski J, Chatla S, Zhang Q, Nayak A, Guha M, Fuchs SY, Thomas C, Chakrabarti R.

Oncogene. 2019 Mar;38(12):2092-2107. doi: 10.1038/s41388-018-0562-z. Epub 2018 Nov 15.

PMID:
30442981
5.

Cigarette Smoke Toxins-Induced Mitochondrial Dysfunction and Pancreatitis Involves Aryl Hydrocarbon Receptor Mediated Cyp1 Gene Expression: Protective Effects of Resveratrol.

Ghosh J, Chowdhury AR, Srinivasan S, Chattopadhyay M, Bose M, Bhattacharya S, Raza H, Fuchs SY, Rustgi AK, Gonzalez FJ, Avadhani NG.

Toxicol Sci. 2018 Dec 1;166(2):428-440. doi: 10.1093/toxsci/kfy206.

PMID:
30165701
6.

A PERK-miR-211 axis suppresses circadian regulators and protein synthesis to promote cancer cell survival.

Bu Y, Yoshida A, Chitnis N, Altman BJ, Tameire F, Oran A, Gennaro V, Armeson KE, McMahon SB, Wertheim GB, Dang CV, Ruggero D, Koumenis C, Fuchs SY, Diehl JA.

Nat Cell Biol. 2018 Jan;20(1):104-115. doi: 10.1038/s41556-017-0006-y. Epub 2017 Dec 11.

7.

Downregulation of the IFNAR1 chain of type 1 interferon receptor contributes to the maintenance of the haematopoietic stem cells.

Gui J, Zhao B, Lyu K, Tong W, Fuchs SY.

Cancer Biol Ther. 2017 Jul 3;18(7):534-543. doi: 10.1080/15384047.2017.1345395. Epub 2017 Jul 5.

8.

Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Zhao B, Bhattacharya S, Yu Q, Fuchs SY.

Leuk Lymphoma. 2018 Jan;59(1):171-177. doi: 10.1080/10428194.2017.1319053. Epub 2017 May 15.

9.

Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment.

Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY.

Cancer Cell. 2017 Feb 13;31(2):194-207. doi: 10.1016/j.ccell.2017.01.004.

10.

PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.

Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA.

PLoS Genet. 2016 Dec 15;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. eCollection 2016 Dec.

11.

A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon.

Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY.

Clin Cancer Res. 2017 Apr 15;23(8):2038-2049. doi: 10.1158/1078-0432.CCR-16-1386. Epub 2016 Sep 28.

12.

Therapeutic Elimination of the Type 1 Interferon Receptor for Treating Psoriatic Skin Inflammation.

Gui J, Gober M, Yang X, Katlinski KV, Marshall CM, Sharma M, Werth VP, Baker DP, Rui H, Seykora JT, Fuchs SY.

J Invest Dermatol. 2016 Oct;136(10):1990-2002. doi: 10.1016/j.jid.2016.06.608. Epub 2016 Jun 29.

13.

Mitochondrial stress-induced p53 attenuates HIF-1α activity by physical association and enhanced ubiquitination.

Chowdhury AR, Long A, Fuchs SY, Rustgi A, Avadhani NG.

Oncogene. 2017 Jan 19;36(3):397-409. doi: 10.1038/onc.2016.211. Epub 2016 Jun 27.

14.

miR-216b regulation of c-Jun mediates GADD153/CHOP-dependent apoptosis.

Xu Z, Bu Y, Chitnis N, Koumenis C, Fuchs SY, Diehl JA.

Nat Commun. 2016 May 13;7:11422. doi: 10.1038/ncomms11422.

15.

Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression.

Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY.

Cell Rep. 2016 Apr 5;15(1):171-180. doi: 10.1016/j.celrep.2016.03.006. Epub 2016 Mar 24.

16.

BRAF Inhibitors and IFNα: Plus, Minus, or Indeterminate?

Davar D, Fuchs SY, Kirkwood JM.

J Natl Cancer Inst. 2016 Feb 5;108(7). pii: djv432. doi: 10.1093/jnci/djv432. Print 2016 Jul. No abstract available.

PMID:
26851801
17.

Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer.

Ortiz A, Fuchs SY.

Cytokine. 2017 Jan;89:4-11. doi: 10.1016/j.cyto.2016.01.010. Epub 2016 Jan 25. Review.

18.

Type I Interferons Control Proliferation and Function of the Intestinal Epithelium.

Katlinskaya YV, Katlinski KV, Lasri A, Li N, Beiting DP, Durham AC, Yang T, Pikarsky E, Lengner CJ, Johnson FB, Ben-Neriah Y, Fuchs SY.

Mol Cell Biol. 2016 Jan 25;36(7):1124-35. doi: 10.1128/MCB.00988-15.

19.

Hemagglutinin of Influenza A Virus Antagonizes Type I Interferon (IFN) Responses by Inducing Degradation of Type I IFN Receptor 1.

Xia C, Vijayan M, Pritzl CJ, Fuchs SY, McDermott AB, Hahm B.

J Virol. 2015 Dec 16;90(5):2403-17. doi: 10.1128/JVI.02749-15.

20.

Type I interferons mediate pancreatic toxicities of PERK inhibition.

Yu Q, Zhao B, Gui J, Katlinski KV, Brice A, Gao Y, Li C, Kushner JA, Koumenis C, Diehl JA, Fuchs SY.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15420-5. doi: 10.1073/pnas.1516362112. Epub 2015 Dec 1.

21.

Type 1 interferons contribute to the clearance of senescent cell.

Katlinskaya YV, Carbone CJ, Yu Q, Fuchs SY.

Cancer Biol Ther. 2015;16(8):1214-9. doi: 10.1080/15384047.2015.1056419. Epub 2015 Jun 5.

22.

ATF4-dependent induction of heme oxygenase 1 prevents anoikis and promotes metastasis.

Dey S, Sayers CM, Verginadis II, Lehman SL, Cheng Y, Cerniglia GJ, Tuttle SW, Feldman MD, Zhang PJ, Fuchs SY, Diehl JA, Koumenis C.

J Clin Invest. 2015 Jul 1;125(7):2592-608. doi: 10.1172/JCI78031. Epub 2015 May 26.

23.

DNA-damage-induced type I interferon promotes senescence and inhibits stem cell function.

Yu Q, Katlinskaya YV, Carbone CJ, Zhao B, Katlinski KV, Zheng H, Guha M, Li N, Chen Q, Yang T, Lengner CJ, Greenberg RA, Johnson FB, Fuchs SY.

Cell Rep. 2015 May 5;11(5):785-797. doi: 10.1016/j.celrep.2015.03.069. Epub 2015 Apr 23.

24.

Type I interferon controls propagation of long interspersed element-1.

Yu Q, Carbone CJ, Katlinskaya YV, Zheng H, Zheng K, Luo M, Wang PJ, Greenberg RA, Fuchs SY.

J Biol Chem. 2015 Apr 17;290(16):10191-9. doi: 10.1074/jbc.M114.612374. Epub 2015 Feb 25.

25.

Trim58 degrades Dynein and regulates terminal erythropoiesis.

Thom CS, Traxler EA, Khandros E, Nickas JM, Zhou OY, Lazarus JE, Silva AP, Prabhu D, Yao Y, Aribeana C, Fuchs SY, Mackay JP, Holzbaur EL, Weiss MJ.

Dev Cell. 2014 Sep 29;30(6):688-700. doi: 10.1016/j.devcel.2014.07.021. Epub 2014 Sep 18.

26.

Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury.

Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Girondo M, Rui H, May MJ, Avadhani NG, Rustgi AK, Fuchs SY.

EMBO Mol Med. 2014 Mar;6(3):384-97. doi: 10.1002/emmm.201303236. Epub 2014 Jan 30.

27.

HCV infection selectively impairs type I but not type III IFN signaling.

Chandra PK, Bao L, Song K, Aboulnasr FM, Baker DP, Shores N, Wimley WC, Liu S, Hagedorn CH, Fuchs SY, Wu T, Balart LA, Dash S.

Am J Pathol. 2014 Jan;184(1):214-29. doi: 10.1016/j.ajpath.2013.10.005. Epub 2013 Nov 9.

28.

A BRISC-SHMT complex deubiquitinates IFNAR1 and regulates interferon responses.

Zheng H, Gupta V, Patterson-Fortin J, Bhattacharya S, Katlinski K, Wu J, Varghese B, Carbone CJ, Aressy B, Fuchs SY, Greenberg RA.

Cell Rep. 2013 Oct 17;5(1):180-93. doi: 10.1016/j.celrep.2013.08.025. Epub 2013 Sep 26.

29.

Eliminative signaling by Janus kinases: role in the downregulation of associated receptors.

Carbone CJ, Fuchs SY.

J Cell Biochem. 2014 Jan;115(1):8-16. doi: 10.1002/jcb.24647. Review.

30.

Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.

Sato T, Tran TH, Peck AR, Girondo MA, Liu C, Goodman CR, Neilson LM, Freydin B, Chervoneva I, Hyslop T, Kovatich AJ, Hooke JA, Shriver CD, Fuchs SY, Rui H.

Oncogene. 2014 Apr 24;33(17):2215-24. doi: 10.1038/onc.2013.172. Epub 2013 May 27.

31.

Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Fuchs SY.

J Interferon Cytokine Res. 2013 Apr;33(4):211-25. doi: 10.1089/jir.2012.0117. Review.

32.

The role of prolactin receptor in GH signaling in breast cancer cells.

Xu J, Sun D, Jiang J, Deng L, Zhang Y, Yu H, Bahl D, Langenheim JF, Chen WY, Fuchs SY, Frank SJ.

Mol Endocrinol. 2013 Feb;27(2):266-79. doi: 10.1210/me.2012-1297. Epub 2012 Nov 28.

33.

ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth.

Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, Qiu B, Zhang H, Cerniglia G, Bi M, Li Y, Gao Y, Liu H, Li C, Maity A, Thomas-Tikhonenko A, Perl AE, Koong A, Fuchs SY, Diehl JA, Mills IG, Ruggero D, Koumenis C.

J Clin Invest. 2012 Dec;122(12):4621-34. doi: 10.1172/JCI62973. Epub 2012 Nov 12.

34.

Protein tyrosine phosphatase 1B is a key regulator of IFNAR1 endocytosis and a target for antiviral therapies.

Carbone CJ, Zheng H, Bhattacharya S, Lewis JR, Reiter AM, Henthorn P, Zhang ZY, Baker DP, Ukkiramapandian R, Bence KK, Fuchs SY.

Proc Natl Acad Sci U S A. 2012 Nov 20;109(47):19226-31. doi: 10.1073/pnas.1211491109. Epub 2012 Nov 5.

35.

Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses.

Bhattacharya S, HuangFu WC, Dong G, Qian J, Baker DP, Karar J, Koumenis C, Diehl JA, Fuchs SY.

Oncogene. 2013 Sep 5;32(36):4214-21. doi: 10.1038/onc.2012.439. Epub 2012 Oct 8.

36.

miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner.

Chitnis NS, Pytel D, Bobrovnikova-Marjon E, Pant D, Zheng H, Maas NL, Frederick B, Kushner JA, Chodosh LA, Koumenis C, Fuchs SY, Diehl JA.

Mol Cell. 2012 Nov 9;48(3):353-64. doi: 10.1016/j.molcel.2012.08.025. Epub 2012 Sep 27.

37.

Ubiquitination-mediated regulation of interferon responses.

Fuchs SY.

Growth Factors. 2012 Jun;30(3):141-8. doi: 10.3109/08977194.2012.669382. Epub 2012 Mar 7. Review.

38.

Hepatitis B virus X protein inhibits extracellular IFN-α-mediated signal transduction by downregulation of type I IFN receptor.

Cho IR, Oh M, Koh SS, Malilas W, Srisuttee R, Jhun BH, Pellegrini S, Fuchs SY, Chung YH.

Int J Mol Med. 2012 Apr;29(4):581-6. doi: 10.3892/ijmm.2012.879. Epub 2012 Jan 3.

39.

A DUB for MITF: no myth, some dubiety.

Fuchs SY.

Pigment Cell Melanoma Res. 2011 Oct;24(5):877-8. No abstract available.

PMID:
22081812
40.

Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor.

Zheng H, Qian J, Baker DP, Fuchs SY.

J Biol Chem. 2011 Oct 14;286(41):35733-41. doi: 10.1074/jbc.M111.263608. Epub 2011 Aug 24.

41.

Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis.

Zheng H, Qian J, Carbone CJ, Leu NA, Baker DP, Fuchs SY.

Blood. 2011 Oct 6;118(14):4003-6. doi: 10.1182/blood-2011-06-359745. Epub 2011 Aug 10.

42.

Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor.

Bhattacharya S, Zheng H, Tzimas C, Carroll M, Baker DP, Fuchs SY.

Blood. 2011 Oct 13;118(15):4179-87. doi: 10.1182/blood-2010-12-325373. Epub 2011 Aug 5.

43.

Ubiquitin and cancer: new discussions for a new journal.

Diehl JA, Fuchs SY, Haines DS.

Genes Cancer. 2010 Jul;1(7):679-80. doi: 10.1177/1947601910383565. No abstract available.

44.

Pathogen recognition receptor signaling accelerates phosphorylation-dependent degradation of IFNAR1.

Qian J, Zheng H, Huangfu WC, Liu J, Carbone CJ, Leu NA, Baker DP, Fuchs SY.

PLoS Pathog. 2011 Jun;7(6):e1002065. doi: 10.1371/journal.ppat.1002065. Epub 2011 Jun 9.

45.

Inflammatory signaling compromises cell responses to interferon alpha.

Huangfu WC, Qian J, Liu C, Liu J, Lokshin AE, Baker DP, Rui H, Fuchs SY.

Oncogene. 2012 Jan 12;31(2):161-72. doi: 10.1038/onc.2011.221. Epub 2011 Jun 13.

46.

Melanoma cell-secreted soluble factor that stimulates ubiquitination and degradation of the interferon alpha receptor and attenuates its signaling.

HuangFu WC, Qian J, Liu C, Rui H, Fuchs SY.

Pigment Cell Melanoma Res. 2010 Dec;23(6):838-40. No abstract available.

47.

The cell biology of the unfolded protein response.

Diehl JA, Fuchs SY, Koumenis C.

Gastroenterology. 2011 Jul;141(1):38-41, 41.e1-2. doi: 10.1053/j.gastro.2011.05.018. Epub 2011 May 24. Review.

48.

Role of p38 protein kinase in the ligand-independent ubiquitination and down-regulation of the IFNAR1 chain of type I interferon receptor.

Bhattacharya S, Qian J, Tzimas C, Baker DP, Koumenis C, Diehl JA, Fuchs SY.

J Biol Chem. 2011 Jun 24;286(25):22069-76. doi: 10.1074/jbc.M111.238766. Epub 2011 May 3.

49.

Ubiquitination-dependent regulation of signaling receptors in cancer.

Huangfu WC, Fuchs SY.

Genes Cancer. 2010 Jul;1(7):725-34. doi: 10.1177/1947601910382901.

50.

Prolactin inhibits activity of pyruvate kinase M2 to stimulate cell proliferation.

Varghese B, Swaminathan G, Plotnikov A, Tzimas C, Yang N, Rui H, Fuchs SY.

Mol Endocrinol. 2010 Dec;24(12):2356-65. doi: 10.1210/me.2010-0219. Epub 2010 Oct 20.

Supplemental Content

Loading ...
Support Center